Kenneth R. Chapman

20.2k total citations · 4 hit papers
379 papers, 13.3k citations indexed

About

Kenneth R. Chapman is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cancer Research. According to data from OpenAlex, Kenneth R. Chapman has authored 379 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Pulmonary and Respiratory Medicine, 191 papers in Physiology and 21 papers in Cancer Research. Recurrent topics in Kenneth R. Chapman's work include Asthma and respiratory diseases (178 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (144 papers) and Respiratory and Cough-Related Research (94 papers). Kenneth R. Chapman is often cited by papers focused on Asthma and respiratory diseases (178 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (144 papers) and Respiratory and Cough-Related Research (94 papers). Kenneth R. Chapman collaborates with scholars based in Canada, United States and United Kingdom. Kenneth R. Chapman's co-authors include Steven Kesten, Anthony S. Rebuck, Nicola A. Hanania, Noé Zamel, Jadwiga A. Wedzicha, Louis‐Philippe Boulet, Donald P. Tashkin, Anthony D’Urzo, Donald Banerji and Jean Bourbeau and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Kenneth R. Chapman

359 papers receiving 12.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

2016 547 citations Jadwiga A. Wedzicha, Donald Banerji et al. profile →
Minimal Clinically Important Differences in Pharmacological Trials

2014 364 citations Paul Jones, Kai Michael Beeh et al. American Journal of Respiratory and Critical Care Medicine profile →
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

2016 350 citations Kenneth R. Chapman et al. profile →
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

2015 325 citations Kenneth R. Chapman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth R. Chapman Canada	65	9.1k	7.9k	807	672	660	379	13.3k
Joan B. Soriano Spain	68	15.5k 1.7×	9.7k 1.2×	648 0.8×	911 1.4×	657 1.0×	361	19.7k
Amund Gulsvik Norway	53	7.8k 0.9×	5.0k 0.6×	590 0.7×	968 1.4×	368 0.6×	218	10.5k
Christine Jenkins Australia	51	16.9k 1.8×	10.6k 1.3×	500 0.6×	580 0.9×	728 1.1×	246	21.1k
Harvey O. Coxson Canada	69	15.1k 1.7×	6.0k 0.8×	364 0.5×	627 0.9×	920 1.4×	209	18.8k
Suzanne S. Hurd United States	22	20.2k 2.2×	10.3k 1.3×	697 0.9×	947 1.4×	1.3k 1.9×	34	24.6k
David C. Johnson United States	22	16.2k 1.8×	8.2k 1.0×	561 0.7×	1.6k 2.4×	1.4k 2.2×	52	21.8k
Leif Bjermer Sweden	59	7.2k 0.8×	7.3k 0.9×	1.8k 2.3×	556 0.8×	1.0k 1.6×	393	12.2k
Huib A.M. Kerstjens Netherlands	60	9.3k 1.0×	7.2k 0.9×	915 1.1×	260 0.4×	694 1.1×	433	12.9k
Donald P. Tashkin United States	85	15.0k 1.6×	9.6k 1.2×	311 0.4×	962 1.4×	1.4k 2.2×	525	24.5k
Barry J. Make United States	58	14.7k 1.6×	6.4k 0.8×	208 0.3×	477 0.7×	715 1.1×	275	17.6k

Countries citing papers authored by Kenneth R. Chapman

Since Specialization

Citations

This map shows the geographic impact of Kenneth R. Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth R. Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth R. Chapman more than expected).

Fields of papers citing papers by Kenneth R. Chapman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth R. Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth R. Chapman. The network helps show where Kenneth R. Chapman may publish in the future.

Co-authorship network of co-authors of Kenneth R. Chapman

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth R. Chapman. A scholar is included among the top collaborators of Kenneth R. Chapman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth R. Chapman. Kenneth R. Chapman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doiron, Dany, Jean Bourbeau, Pei Zhi Li, et al.. (2025). COPD Exacerbations, Air Pollutant Fluctuations, and Individual-Level Factors in the Pandemic Era. International Journal of COPD. Volume 20. 735–751.

Stockley, R A, Ingrid Louise Titlestad, Hanan Tanash, et al.. (2023). Alvelestat, an Oral Neutrophil Elastase Inhibitor in Alpha-1 Antitrypsin Deficiency (AATD): Results of a Phase II Trial. A4493–A4493.

Chow, Ronald, James Im, Kenneth R. Chapman, et al.. (2023). Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) – A Systematic Review. International Journal of COPD. Volume 18. 2581–2617. 10 indexed citations

Ross, Bryan, Dany Doiron, Andrea Benedetti, et al.. (2023). Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. Thorax. 78(10). 974–982. 12 indexed citations

Cherian, Mathew, Dennis Jensen, Wan C. Tan, et al.. (2021). Dyspnoea and symptom burden in mild–moderate COPD: the Canadian Cohort Obstructive Lung Disease Study. ERJ Open Research. 7(2). 960–2020. 12 indexed citations

Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2019). Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration. Journal of Allergy and Clinical Immunology. 143(2). AB102–AB102. 4 indexed citations

Chapman, Kenneth R., John R. Hurst, Stefan Frent, et al.. (2018). Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 198(3). 329–339. 171 indexed citations

Roche, Nicolás, Kenneth R. Chapman, Claus Vogelmeier, et al.. (2017). Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine. 195(9). 1189–1197. 116 indexed citations

Labonté, Laura, Wan C. Tan, Pei Z. Li, et al.. (2016). Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine. 194(3). 285–298. 91 indexed citations

10.

Tan, Wan C., Don D. Sin, Jean Bourbeau, et al.. (2015). Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax. 70(9). 822–829. 173 indexed citations

11.

Jones, Paul, Kai Michael Beeh, Kenneth R. Chapman, et al.. (2014). Minimal Clinically Important Differences in Pharmacological Trials. American Journal of Respiratory and Critical Care Medicine. 189(3). 250–255. 364 indexed citations breakdown →

12.

Chapman, Kenneth R., et al.. (2014). QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 2(1). 48–60. 7 indexed citations

13.

Labonté, Laura, Wan C. Tan, Robert Cowie, et al.. (2013). Measuring exacerbations in subjects with mild to moderate COPD from a population-based cohort: The CanCOLD study. European Respiratory Journal. 42(Suppl 57). P4226–P4226. 1 indexed citations

14.

Wong, Jean, Amir Abrishami, Yiliang Yang, et al.. (2012). A Perioperative Smoking Cessation Intervention with Varenicline. Anesthesiology. 117(4). 755–764. 67 indexed citations

15.

Day, Anna, et al.. (2006). Women and Asthma: Lessons from a Gender Analysis of the Asthma in Canada Survey. Journal of Asthma. 43(2). 169–173. 10 indexed citations

16.

Ferreira, Ivone, Mehdi S. Hazari, Carlos Cano, Noé Zamel, & Kenneth R. Chapman. (2001). Exhaled Nitric Oxide and Hydrogen Peroxide in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 164(6). 1012–1015. 82 indexed citations

17.

Chatkin, José Miguel, Khalil Ansarin, Philip E. Silkoff, et al.. (1999). Exhaled Nitric Oxide as a Noninvasive Assessment of Chronic Cough. American Journal of Respiratory and Critical Care Medicine. 159(6). 1810–1813. 128 indexed citations

18.

Silkoff, Philip E., José Miguel Chatkin, Khalil Ansarin, et al.. (1999). Exhaled Nitric Oxide after β2-agonist Inhalation and Spirometry in Asthma. American Journal of Respiratory and Critical Care Medicine. 159(3). 940–944. 132 indexed citations

19.

Ungar, Wendy J., et al.. (1998). The Patient Level Cost of Asthma in Adults in South Central Ontario. Canadian Respiratory Journal. 5(6). 463–471. 31 indexed citations

20.

Garfinkel, Susan, Steven Kesten, Kenneth R. Chapman, & Anthony S. Rebuck. (1992). Physiologic and Nonphysiologic Determinants of Aerobic Fitness in Mild to Moderate Asthma. American Review of Respiratory Disease. 145(4_pt_1). 741–745. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact